Cencora Earnings Call: Specialty Strength, Guidance Raised

Cencora, Inc. ((COR)) has held its Q1 earnings call. Read on for the main highlights of the call.

Cencora Signals Strong Momentum With Upgraded 2026 Outlook Despite Near-Term Pressures

Cencora’s latest earnings call struck a notably upbeat tone, underscoring broad-based growth, successful execution on recent acquisitions, and a confident upgrade to 2026 guidance. Management highlighted rising revenue, gross profit, adjusted EPS, and operating income, with specialty drugs and managed services organizations (MSOs) such as OneOncology and Retina Consultants of America (RCA) driving much of the momentum. While acknowledging higher operating and interest expenses, seasonal cash outflows, and some customer churn, executives repeatedly framed these as transitory headwinds against a backdrop of strengthening fundamentals and an expanding specialty platform.

Revenue Growth and Raised Top-Line Guidance

Cencora reported consolidated revenue of $85.9 billion for the quarter, a 5.5% year-over-year increase, and raised its full-year consolidated revenue growth guidance to a robust 7%–9%, up from 5%–7%. Management attributed the uplift to stronger-than-expected performance across its reportable segments as well as incremental contributions from the newly consolidated OneOncology business. The raise signals confidence that Cencora can sustain mid- to high-single-digit top-line expansion even as it digests large acquisitions and navigates customer off-boarding.

Earnings and Operating Income Expansion

Profitability showed even more momentum than revenue. Adjusted diluted EPS came in at $4.08, up 9% from the prior-year quarter, while consolidated operating income climbed 12%. Reflecting this strength, the company raised its full-year consolidated adjusted operating income growth outlook to 11.5%–13.5%, up from 8%–10%. The widening gap between revenue growth and operating income growth suggests operating leverage is kicking in as the company scales its specialty and MSO platforms, even while absorbing higher costs tied to acquisitions and growth investments.

US Healthcare Solutions as the Growth Engine

The US Healthcare Solutions segment remained the core driver of Cencora’s performance. Segment revenue increased 5% to $76.2 billion, while operating income surged 21% to $831 million. Management credited specialty growth, strong volumes from health systems, solid physician practice sales, contributions from RCA, and early positive results from the OneOncology acquisition. In response, the company raised full-year US operating income growth guidance to 14%–16%, underlining the strategic importance of the US platform and its specialty-heavy mix.

Gross Profit and Margin Improvement

Gross profit rose 18% year-over-year to $3.0 billion, outpacing revenue growth and lifting the consolidated gross margin to 3.48%, a 37 basis point improvement. The RCA acquisition was singled out as a key contributor to this margin expansion, reflecting the higher-margin nature of MSO and specialty services relative to traditional distribution. This margin trajectory is particularly important for investors, as it suggests Cencora’s strategy of deepening its specialty and services footprint is translating into tangible profitability gains.

Specialty Product Momentum Driven by GLP-1s

Specialty drugs, especially GLP-1 therapies, remain a major tailwind. GLP-1 products grew by $1.0 billion, or 11%, versus the prior-year quarter, helping power the US segment’s performance. While these therapies can be volatile given policy and reimbursement dynamics, Cencora’s strong position in the channel is currently a meaningful growth driver, reinforcing its role as a key intermediary in high-demand, complex therapies.

Strategic Acquisitions and MSO Expansion

Cencora continued to build out its MSO footprint, completing the acquisition of a majority stake in OneOncology, increasing its ownership from 35% to 92%, with approximately 8% retained by practices and management. The company also marked the one-year anniversary of the RCA acquisition. Management expects OneOncology to be roughly neutral to adjusted EPS over its first 12 months under full consolidation, but to become a meaningful contributor to operating income thereafter, and to add around $30 million to other income, offset by noncontrolling interest impacts. These moves deepen Cencora’s integration into physician practices and oncology networks, positioning it to capture value beyond traditional wholesale distribution.

Improving Full-Year Cash Flow Outlook

Despite posting negative adjusted free cash flow of $2.4 billion in the quarter due to typical seasonal working capital needs, Cencora’s cash profile is improving. The outflow was better than the negative $2.8 billion in the prior-year quarter, and management reiterated expectations for approximately $3.0 billion in adjusted free cash flow for the full year as working capital normalizes. For investors, the message is that the quarter’s cash burn is seasonal rather than structural, with a stronger cash generation runway over the remainder of the fiscal year.

Higher Operating Expenses Reflect Growth Investments

Consolidated operating expenses climbed about 22% to $1.9 billion in the quarter, driven primarily by the consolidation of RCA and spending to support revenue and specialty growth. While the step-up in costs pressured margins at the operating expense line, management framed these outlays as strategic investments in capabilities and scale, particularly in MSO, specialty, and service offerings that carry higher gross margins and long-term earnings potential.

Rising Interest Expense and Debt Burden

Financing the recent acquisitions has notably increased Cencora’s interest costs. Net interest expense rose to $72 million in the quarter, up $44 million year-over-year. The company lifted its full-year interest expense guidance to $480–$500 million, up from $315–$335 million, and flagged that second-quarter interest expense is expected to be roughly double the first quarter due to seasonal working capital and related financing. While manageable within the broader earnings growth story, these higher interest costs are a tangible drag on net income and underscore the importance of the company’s stated focus on deleveraging.

Negative Free Cash Flow in the Quarter

Adjusted free cash flow of negative $2.4 billion reflected the highly seasonal nature of Cencora’s working capital, particularly in the first quarter. Management stressed that this pattern is consistent with historical trends and pointed to the improvement from last year’s negative $2.8 billion. Investors will be watching closely to see if the company delivers on its full-year $3.0 billion free cash flow target, which would support debt reduction and future capital returns once the current deleveraging phase progresses.

International Operating Income Pressure

The International Healthcare Solutions business was a notable soft spot. Operating income declined 14% on an as-reported basis and 17% on a constant currency basis to $142 million. Management attributed the weakness to the timing of manufacturer price adjustments in a developing market country, emphasizing that the issue was timing-related rather than structural. While the international top line is still expected to grow mid- to high-single digits, the near-term profit dip highlights ongoing volatility in certain markets and underscores why the company did not revise international operating income guidance.

Customer Losses and Off-boarding Headwinds

Cencora also faced some customer-specific headwinds. Revenue comparisons were negatively impacted by the off-boarding of a large grocery customer in 2025 and the loss of an oncology customer following its acquisition by a competitor. Management indicated these factors are affecting quarter-to-quarter cadence, particularly in the second and third quarters. Although these losses are a drag on near-term revenue growth, the impact is being offset by strength in specialty, health systems, and MSO-driven growth, supporting the company’s raised full-year outlook.

Pause on Share Repurchases to Prioritize Deleveraging

In a notable capital allocation shift, Cencora has paused share repurchases to prioritize paying down debt after the OneOncology acquisition. The diluted share count at quarter-end was 195.3 million, roughly flat year-over-year. Management’s plan to focus on deleveraging in the near term means investors should not expect buybacks to support EPS in the short run, but the strategy reflects a disciplined balance-sheet approach amid elevated interest costs and recent M&A.

Asset Impairment and Legacy Consulting Weakness

The company recorded a full impairment of depreciable assets in its US consulting business as of December 31, 2025, and saw revenue and operating income decline in its legacy US hub consulting services. These dynamics contributed to a 6% drop in operating income in the “Other” segment. While not central to the overall investment case, the impairment and ongoing weakness suggest Cencora is refocusing away from lower-performing consulting operations toward higher-growth, higher-margin businesses such as specialty distribution and MSO services.

Upgraded 2026 Guidance and Forward-Looking Outlook

For fiscal 2026, Cencora reaffirmed adjusted diluted EPS guidance of $17.45–$17.75, building off the first-quarter adjusted EPS of $4.08. The company raised consolidated revenue growth guidance to 7%–9% and consolidated operating income growth to 11.5%–13.5%, signaling confidence in sustained margin expansion. US Healthcare Solutions operating income is now expected to grow 14%–16%, while International revenue is projected to rise 7%–9% as reported (6%–8% constant currency) with flat operating income guidance maintained. The “Other” segment is expected to deliver 1%–5% revenue growth with flat operating income. Financial assumptions include interest expense of $480–$500 million, an effective tax rate around 20%, roughly $3 billion in full-year adjusted free cash flow, and a continued pause on share repurchases as the company emphasizes deleveraging. OneOncology is expected to be neutral to adjusted EPS in its first 12 months but to support operating income growth and contribute to other income, adding to the longer-term earnings trajectory.

Cencora’s earnings call painted a picture of a company leaning into its strengths in specialty distribution and physician-focused MSOs while carefully managing the financial impacts of recent acquisitions and seasonal working capital swings. Upgraded revenue and operating income guidance, strong US segment performance, and improving gross margins stood out as clear positives, even as higher interest expense, international timing issues, and customer off-boarding create some near-term noise. For investors, the key takeaway is that underlying business momentum and strategic positioning appear solid, with management betting that disciplined deleveraging today and continued specialty expansion will translate into stronger, more sustainable earnings power over the coming years.